Verona Pharma plc
DelistedCIK 1657312fmd_1EZNET0D5DVSQKW9NMX0SVV75NManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Jun 30, 2025, 29 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 40 | 0 | 0 | 42 |
| Cost of revenue | – | – | 0 | 0 | 0 | – |
| Gross profit | – | – | 40 | 0 | 0 | – |
| Research and development | 42 | 45 | 79 | 49 | 17 | 45 |
| Total operating expenses | 52 | 74 | 113 | 76 | 68 | 197 |
| Operating income | (52) | (74) | (73) | (76) | (68) | (155) |
| Interest expense | 0 | 0 | 0 | 1 | 2 | 24 |
| Other non-operating income (expense) | 12 | 9 | 18 | 7 | 14 | (9) |
| Income before taxes | (40) | (65) | (56) | (68) | (54) | (163) |
| Income tax expense | 0 | 0 | (0) | 0 | 0 | 10 |
| Net income from continuing operations | (41) | (65) | (56) | (69) | (54) | (173) |
| Net income | (41) | (65) | (56) | (69) | (54) | (173) |
| Net income to common shareholders | (41) | (65) | (56) | (69) | – | – |